---
document_datetime: 2024-05-07 12:26:59
document_pages: 31
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 19.147972
conversion_datetime: 2025-12-30 09:57:57.299865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0097              | Submission of the final report from study D8110C00001 listed as a category 3 study in the RMP (SOB/020). This is a phase III, randomised, placebo-controlled study of AZD1222 (Vaxzevria) conducted in the US, Peru and Chile. The purpose of the final CSR addendum is to provide long-term | 07/03/2024                                  | n/a                                         |                                  |           |

Vaxzevria Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | safety data through to study completion and include the second year of follow-up post-first dose and final day 730 visit. The RMP version 8 succession number 3 was submitted to consolidate the updates made in RMP as part of two parallel procedures (EMEA/H/C/005675/II/0096 and EMEA/H/C/005675/II/0097). In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone date for study D8111R00010. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                             | longer authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0096 | Update of sections 4.8 and 5.1 of the SmPC based on final results from study D7220C00001; this is a phase 2/3 partially double-blinded, randomised, multinational, active-controlled study in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of SARS-CoV-2. The RMP version 8 succession number 3 was submitted to consolidate the updates made in RMP as part of two parallel procedures (EMEA/H/C/005675/II/0096 and EMEA/H/C/005675/II/0097). In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone date for study D8111R00010. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance 07/03/2024 Medicinal product | SmPC Submission of the final study results of study D7220C00001. The interim analysis results for the Boost Cohort of Study D7220C00001 were submitted previously based on a data lock point of 11 October 2021. These data were assessed within the procedure EMEA/H/C/005675/II/0052, and consequently, the product information was updated including the possibility of administering Vaxzevria as a homologous or heterologous booster (in subjects who previously had received an mRNA vaccine). In this procedure, the final study results have been submitted. The results from the final analysis are consistent with those provided with the interim analysis. No new safety concern has been identified. Minor labelling updates, such as, for example, update of the percentages of adverse drug reactions, neutralising antibody titres and GMT ratio, have been implemented in Sections 4.8 and 5.1. no |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                     |            |               | For more information, please refer to the Summary of Product Characteristics.                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0098/G           | This was an application for a group of variations. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                   | 13/12/2023 |               | SmPC, Annex II, Labelling and PL authorised                                                                                                            |
| PSUSA/10912 /202212 | Periodic Safety Update EU Single assessment - COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)                                                                                                                                                                                                                                                                                                     | 20/07/2023 | 15/09/2023    | SmPC and PL Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10912/202212. |
| IB/0094             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                   | 07/08/2023 | n/a no longer |                                                                                                                                                        |
| IB/0093             | B.I.d.z - Stability of AS - Other variation                                                                                                                                                                                                                                                                                                                                                              | 07/08/2023 | n/a           |                                                                                                                                                        |
| II/0090             | Submission of the final report from study D8111R00007 (RAVEN) listed as a category 3 study in the RMP. This is an observational retrospective cohort study using secondary databases to establish effectiveness of Vaxzevria in England. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal product | 20/07/2023 | n/a           |                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0089   | Update of sections 4.8 of the SmPC in order to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/07/2023   | 15/09/2023   | SmPC and PL   | SmPC new text                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           | update the frequencies of 'dizziness' and 'abdominal pain' in the list of adverse drug reactions (ADRs) to common and the frequency of 'fever' to very common based on final results and final pooled analysis for studies COV001, COV002, COV003 and COV005. Update of section 5.1 of the SmPC in order to update safety and efficacy information, based on final results and final pooled analysis for studies COV001, COV002, COV003 and COV005 as well as the final manuscript for COV004, listed as category 3 studies in the RMP. Study COV001 is phase I/II, single-blind, randomised, active-controlled, multicenter study in healthy adults aged 18-55 years; Study COV002 is a phase II/III, single-blind, randomised, active-controlled, multicenter study in adults ≥ 18 years of age and at high risk of exposure to COVID-19; Study COV003 is a phase III, single- blind, randomised, controlled, multicenter study in adults ≥ 18 years of age at high risk of exposure to SARS-CoV-2; Study COV005 is a phase I/II, double- blind, randomised, placebo-controlled, multicenter study in adults 18 to 65 years of age with or without HIV. Study COV004 a phase IB/II single-blind, randomized controlled trial of the (AZD1222) vaccine in adults in Kenya. The Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product |              | no           |               | The MAH has submitted the final pooled analysis of the safety, durability of efficacy, and immunogenicity of primary vaccination with AZD1222, based on data collected for up to 12 months after the first dose in studies COV001, COV002, COV003 and COV005 with a data cut-off (DCO) of 31 December 2021. In addition, the MAH provided the individual clinical study reports (CSRs) for COV001, COV002, COV003 and COV005 that summarise durability of efficacy results and cumulative immunogenicity and safety results. Overall, the final pooled vaccine efficacy (VE) results demonstrate an estimated durability of VE consistent with the previously submitted primary pooled analysis estimates of VE against SARS-CoV-2 virologically confirmed symptomatic illness, severe disease and death. The final pooled immunogenicity analysis provided similar results to those obtained at the time of the initial conditional marketing authorisation, both in terms of GMTs and seroconversion rates reached after first and second dose regardless of the humoral immunological assay used. The safety evaluation based on the results presented from the updated pooled analysis does not differ substantially from those submitted at the time of the conditional marketing authorisation. A higher reactogenicity (both local and systemic events) was observed in participants in the in AZD1222 group compared to those in the control group. These events were reported less frequently and milder after the second dose than after the first dose. Similarly, unsolicited adverse events (AE) were reported more frequently in AZD1222 group than in control group. The majority were mild to moderate in severity and were longer authorised |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                   | reported less frequently after the second dose in both AZD1222 and the comparator. Overall frequencies of either solicited local and systemic AEs and unsolicited AEs remain barely unchanged to those initially provided, except for 'dizziness' and 'abdominal pain' which frequency has increased from uncommon to common and 'fever' which frequency has increased from common to very common. For more information, please refer to the Summary of Product Characteristics. authorised   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0091             | Submission of the final report from study D8111R00020 listed as a category 3 study in the RMP. This is a systematic literature review of observational studies evaluating safety after vaccination with Vaxzevria in patients taking immunosuppressant medications and/or with primary immunodeficiency. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority product | 08/06/2023 | n/a no     | longer            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0092/G           | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code A.7 - Administrative change - Deletion of manufacturing sites Medicinal                                                                                                                                                                                                                                                                       | 12/05/2023 | 15/09/2023 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10912 /202206 | Periodic Safety Update EU Single assessment - COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)                                                                                                                                                                                                                                                                                                                                                           | 26/01/2023 | 09/03/2023 | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |               |                 | PSUSA/10912/202206.                                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------|------------------------------------------------------------------------------------------|
| II/0084/G | This was an application for a group of variations. Submission of an updated RMP version 6 succession 3 in order to request the discontinuation of the category 1 study D8111C00010 and remove it from the Annex II; this is an interventional safety study of AZD1222 vaccine in immunocompromised adults. In addition, the important potential risk of 'Nervous system disorders, including immune mediated neurological conditions' has been amended to 'Immune mediated neurological conditions', due dates of additional pharmacovigilance activities have been updated and other editorial wordings of the RMP have been implemented. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal product | 09/02/2023 | 15/09/2023 no | Annex II longer | For more information, please refer to the Summary of Product Characteristics. authorised |
| IB/0086   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/01/2023 | n/a           |                 |                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | re-test period/storage period supported by real time data                                                                                           |                    |               |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0087 | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol          | 21/12/2022         | n/a           |                                         | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0085 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                       | 06/12/2022         | n/a           |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0079  | Renewal of the marketing authorisation.                                                                                                             | 13/10/2022 product | 31/10/2022 no | SmPC, Annex II, Labelling and PL longer | Summary The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have been fulfilled or reclassified as Recommendations or Category 3 studies in the RMP, there are no remaining grounds for the marketing authorisations to remain conditional and therefore recommends the granting of the MA no subject to Specific Obligations for Vaxzevria. Please refer to Scientific Discussion 'Vaxzevria/H//C/005675/R/0079' |
| IB/0081 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Medicinal | 07/10/2022         | 20/10/2022    | SmPC                                    | To extend the shelf life of the finished product from 6 months to 9 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0075 | Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months                                            | 15/09/2022         | 20/10/2022    | SmPC                                    | SmPC new text Updated efficacy analysis were performed with additional                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. In addition, the MAH took the opportunity to implement other administrative updates in the product information.  The RMP version 5.2 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other administrative updates. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data confirmed COVID-19 cases accrued during blinded placebo controlled follow up, representing up to 6 months follow-up data (data cut-off date: 30 July 2021). The analysis of the primary efficacy endpoint for the double-blind period included 325 adjudicated events occurring at least 15 days post second dose of study vaccine. There were 141 events in the AZD1222 group and 184 events in the placebo group, with a vaccine efficacy (VE) estimate of 66.98% and a lower bound of the 95% CI of 58.87%. In participants between 18 to and 65 years of age, a VE estimate of 64.76% and a lower bound of the 95% CI of 55.73%. In participants older than 65 years of age, a VE estimate of 86.35% and a lower bound of the 95% CI of 65.79%.  The SmPC section 5.1 has been updated with a summary of these results. Four secondary endpoints were analysed for events at least 15 days post second dose of study intervention, and all 4 results were generally consistent with the primary analysis. In participants with or without evidence of prior infection, the VE was 66.96%. VE against severe or critical symptomatic COVID-19 was 95.69%. In relation to the incidence of COVID-19 related emergency departments visits, a VE of 94.17% was shown. The incidence of the first post treatment response for SARS-CoV-2 nucleocapsid antibodies occurring at least 15 days after the second dose of study intervention, regardless of symptoms, resulted in a VE estimate of 61.01%. Medicinal product no longer authorised

The safety data reported from the 6-months follow-up did not reveal new safety concerns for AZD1222.  The most common adverse drug reactions (ADR) were consistent with the adverse reactions commonly observed following

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | vaccination which were already included in the SmPC. The benefit-risk balance of Vaxzevria, remains positive. For more information, please refer to the Summary of Product Characteristics. n/a authorised   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0076/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test 01/09/2022 no                                                                                      | longer                                                                                                                                                                                                       |
| II/0038   | method at the site is a biol/immunol method Submission of the final report from study MS1222- 0003 ''Assessment of anti-PF4 antibodies prior to, and following, vaccination with AZD1222\" listed as a category 3 study in the RMP. This is a study where sera of vaccinated individuals in study D8110C00001 are tested to elucidate whether vaccination with Vaxzevria leads to increased levels of circulating anti-PF4 antibodies, a key component of the hypothesized mechanism underlying thrombosis with thrombocytopenia syndrome (TTS). C.I.13 - Other variations not specifically covered 01/09/2022 Medicinal product | n/a                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                          |            |               |                 |                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0080             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                       | 26/08/2022 | n/a           |                 |                                                                                                                                                                                                                                                    |
| PSUSA/10912 /202112 | Periodic Safety Update EU Single assessment - COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)                                                                                                                                                                                                                                                                                                                | 21/07/2022 | 08/08/2022    | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10912/202112. authorised                                                                                              |
| IB/0078/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product product | 05/08/2022 | 20/10/2022 no | Annex II longer | Updated annex II with a new manufacturing site for the active substance mAbxience S.A.U, Calle Jose Zabala 1040, Garin, B1619JNA, Buenos Aires, Argentina                                                                                          |
| II/0071             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS Medicinal                                                                                                                                                                                                                    | 21/07/2022 | n/a           |                 |                                                                                                                                                                                                                                                    |
| II/0031             | Submission of the final study report for MS1222- 0002 'In Vitro Assay to Determine Release of Spike Protein From Transduced Cells' to fulfil the imposed study as reflected in Annex II of the product information and the RMP. As a result, Annex II of the                                                                                                                                                        | 21/07/2022 | 08/08/2022    | Annex II        | SmPC new text Within this type II variation, the MAH submits the final study report for study MS1222-0002 which fulfils the Annex II obligation as well as the Post-Authorisation Measure (PAM) 'In Vitro expression of Spike protein' as detailed |

<div style=\"page-break-after: always\"></div>

|         | product information is being updated to remove this study. The MAH is taking the opportunity to provide two additional studies linked to support the investigation on the platelet activation: the final study report for MS1222-0001 'Computational Prediction of Spike Protein Interaction with Platelet Factor 4 (PF4)' which is the first report requested within the required studies for \"in vitro interaction of AZD1222 or spike protein with PF4 and/or platelets\" as reflected in the RMP; and the study report for 520447 \"Investigative Vaccine Study in the Mouse\" to evaluate spike protein levels and haematology parameters. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated product   | no longer   | under Additional Pharmacovigilance Activities in the EU Risk Management Plan (RMP) for Vaxzevria. This in vitro assay was conducted to determine the release of spike protein from transduced cells. The study results show that spike protein is produced by AZD1222-transduced cells, which is cleaved and released from the cell surface. The lack of full- length spike protein detection in the supernatant and the fact that lactate dehydrogenase (LDH) levels did not rise with multiplicities of infection (MOI) suggests that the presence of shed spike protein was not responsible of cell death. In view of the data submitted with the variation, the above mentioned obligation has been fulfilled, and therefore it is recommended that it is deleted from the Annex II. For more information, please refer to the Summary of Product Characteristics. authorised   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0074 | Type II C.I.11.b, To update Annex IIE to remove the specific obligation relating to provision of process validation data for the active substance and finished product (SO1) which has been fulfilled, and to change the date of the specific obligation relating to the provision of additional information on stability of the active substance and finished product (and review the finished product specifications following further manufacturing experience) from June 2022 to 23/06/2022 Medicinal                                                                                                                                                                                                                                                                                                                                                  | 08/08/2022  | To address specific obligations on quality, the MA Holder provided relevant data in line with the requirements and due dates set by CHMP. Protocols and reports were provided in monthly Post Authorisation Measures since initial authorisation (2021) until March 2022, and a number of variations were submitted. The information provided by the MA Holder in these submissions was evaluated and the specific obligation relating to provision of process validation data is now considered fulfilled. Stability studies are                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | January 2023 (SO2). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                            | longer                            | ongoing and further data from these studies are expected to be submitted in due course. The Annex IIE has been updated as follows: • SO1 (relating to provision of process validation data for the active substance and finished product) is deleted from the list of specific obligations. • SO2 (relating to the provision of additional information on stability of the active substance and finished product (and review the finished product specifications following further manufacturing experience), due date is extended from June 2022 to January 2023. authorised   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0077 | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/06/2022 n/a                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0052 | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 19/05/2022 20/05/2022 SmPC and no | Please refer to Scientific Discussion 'EMEA/H/C/005675/II/0052' For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0073   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                           | 21/04/2022    | n/a            |                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------|------------------------------|
| IB/0072   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/04/2022    | n/a authorised | in the manufacturing process |
| II/0064/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method product | 07/04/2022 no | n/a longer     |                              |
| II/0062   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol Medicinal                                                                                                                                                                                                                                                                                               | 07/04/2022    | n/a            |                              |

<div style=\"page-break-after: always\"></div>

| IB/0069   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                    | 23/03/2022   | 31/03/2022   | Annex II   | To change the due date for the final clinical study reports for studies COV001, COV002, COV003 and COV005 and for the final analysis from the pooled pivotal studies listed as specific obligation in Annex IIE from 31 May 2022 to 31 December 2022. authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0063   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                        | 04/03/2022   | n/a          |            |                                                                                                                                                                                                                                                                    |
| IB/0065/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place product | 25/02/2022   | n/a no       | longer     |                                                                                                                                                                                                                                                                    |
| IB/0068   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                      | 17/02/2022   | n/a          |            |                                                                                                                                                                                                                                                                    |
| IB/0066   | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation Medicinal                                                                                                                                                                                                                                                                                                                                                                                   | 11/02/2022   | n/a          |            |                                                                                                                                                                                                                                                                    |
| IB/0060/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure                                                                                                                                                                                                                                                                                                                            | 07/02/2022   | n/a          |            |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                   |               |                |                 | authorised                                                                                                                                                                                                                                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0067   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                     | 01/02/2022    | 02/02/2022     | SmPC and PL     | Sections 4.4 and 4.8 of the SmPC and sections 2 & 4 of the PL have been updated to implement wording in relation to transverse myelitis                                                                                                                                    |
| IB/0059   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                      | 26/01/2022    | 02/02/2022     | Annex II longer | Update of Annex IIE to extend the due date for a specific obligation (SO13) from December 2021 to March 2022                                                                                                                                                               |
| II/0061/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability product | 20/01/2022 no | n/a 14/01/2022 | SmPC and PL     | Based on post-marketing data with data cut-off 30th September 2021, 1809 cases of thrombosis and thrombocytopenia syndrome (TTS) have been identified, of which 166 were reported after the second dose. Overall TTS reporting rate following dose 2 was estimated at 1.87 |
| II/0055   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal                                                                                                                                                                                                                                        | 13/01/2022    |                |                 | cases/million doses administered, which is lower than the                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                          |            |        | estimated reporting rate after dose 1 (14.45/million doses) and also lower than preliminary estimates of the background rate (5.62-10.75/million person-years). No new unexpected safety findings regarding the events of thrombosis with TTS have been identified. authorised   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10912 /202106 | Periodic Safety Update EU Single assessment - COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)                                                                                                                                                                                                     | 13/01/2022 | n/a    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                |
| IB/0058             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                   | 17/12/2021 | n/a    | longer                                                                                                                                                                                                                                                                           |
| II/0047             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                            | 16/12/2021 | n/a no |                                                                                                                                                                                                                                                                                  |
| IB/0054             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation product                                                                                                                                                                                       | 06/12/2021 | n/a    |                                                                                                                                                                                                                                                                                  |
| II/0040             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal | 02/12/2021 | n/a    |                                                                                                                                                                                                                                                                                  |
| IB/0057             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                             | 30/11/2021 | n/a    |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0053   | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                                                                                                                  | 24/11/2021   | n/a        |             | authorised                                                                                                                                                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0056   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/11/2021   | 23/11/2021 | SmPC and PL | Section 4.4 and 4.8 of the SmPC and sections 2 & 4 of the PL have been updated to implement wording agreed by PRAC in relation to the Events of cerebrovascular venous and sinus thrombosis without thrombocytopenia |
| II/0051/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method Medicinal product | 18/11/2021   | n/a no     | longer      |                                                                                                                                                                                                                      |
| II/0050   | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18/11/2021   | n/a        |             |                                                                                                                                                                                                                      |
| R/0037    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/10/2021   | 09/11/2021 | SmPC,       | The CHMP, having reviewed the available information on                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | 03/11/2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Labelling and PL Specific to   | the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Vaxzevria, subject to the Obligations and Conditions as laid down in Annex II the opinion. authorised   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0049/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                          | n/a no longer                  |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0035/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a 03/11/2021 Medicinal product | n/a                            |                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | biological AS                                                                                                                                                                                                                                                                                                                                                                                                                         |            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 14/10/2021 | n/a                                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0026   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product                                                                                                                                                                                                                                                                                                   | 14/10/2021 | 15/10/2021 SmPC, Annex II and PL no longer | The MAH has provided the primary analysis of study D8110C00001. This is a randomised, double-blinded, placebo-controlled phase III study conducted in the United States, Peru and Chile aimed to assess the efficacy, safety and immunogenicity of Vaxzevria. The vaccine efficacy (VE) results against COVID-19 symptomatic disease was 74.0% (95%CI: 65.3 - 80.5). The VE estimate was also determined in participants ≥65 years of age [VE: 83.5% (95%CI: 54.2 - 94.1)]. Severe or critical symptomatic COVID-19 disease was also evaluated. No cases of severe or critical symptomatic COVID-19 were reported in the vaccine group compared with 8 cases reported in the placebo group. Overall, the observed safety profile is in line with the results included in the product information. The study results led to the addition of the following adverse drug reactions (with their respective frequencies) in the product information: facial paralysis (rare) and muscle spasms (uncommon). |

<div style=\"page-break-after: always\"></div>

| IAIN/0048   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                  | 13/10/2021   | 15/10/2021    | SmPC and PL   | Sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL have been updated to implement signal recommendations on Immune Thrombocytopenia                                                                                                                                                                                                            |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0046     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                   | 27/09/2021   | 15/10/2021    | Annex II      | Update of Annex II A of the product information to remove reference to the temporary testing exemption.                                                                                                                                                                                                                                                     |
| IB/0045     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                            | 17/09/2021   | n/a           |               | authorised                                                                                                                                                                                                                                                                                                                                                  |
| IB/0042     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                  | 17/09/2021   | n/a           | longer        |                                                                                                                                                                                                                                                                                                                                                             |
| IB/0044     | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                  | 13/09/2021   | 14/09/2021 no | SmPC and PL   | • To update section 4.8 of the SmPC and sections 2 & 4 of the PL to implement wording agreed by PRAC in relation to Guillain-Barre Syndrome. • To remove text from section 4.4 of the SmPC and section 2 of the PL in relation to TTS (Thrombosis with thrombocytopenia syndrome and coagulation disorders occurred mostly in women under 60 years of age). |
| IB/0041     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS product                                                                                                                                        | 06/09/2021   | n/a           |               |                                                                                                                                                                                                                                                                                                                                                             |
| II/0032/G   | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test Medicinal | 13/08/2021   | n/a           |               |                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | method at the site is a biol/immunol method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process 11/08/2021                                                                                                                                                                                                                                                                                                                                                           |
| IB/0036   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place 27/07/2021 no                                                                                                                                                                                                                                                                                                                  |
| II/0033/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch 27/07/2021 Medicinal product |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |               |                       | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017/G | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product                                           | 22/07/2021 | 14/09/2021 no | SmPC and Annex II     | To update information about pregnancy and breastfeeding information in section 4.6 of the SmPC as a result of the development and reproductive toxicity (DART) study to indicate that animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development animal studies, and that lactational transfer of anti-SARS-CoV-2 S antibodies from maternal female mice to pups was observed. It is unknown whether Vaxzevria is excreted in human milk. Based on the DART study, section 5.3 of the SmPC is also updated to indicate that vaccine elicited detectable anti- SARS-CoV-2 S-glycoprotein maternal antibodies were transferred to the foetuses and pups, indicating placental and lactational transfer, respectively. No Vaxzevria data are available on vaccine excretion in milk. Section 5.3 was also update to reflect in more detail the outcome from the repeat-dose toxicity study in mice, where intramuscular administration of Vaxzevria was well tolerated. longer |
| IB/0034   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the Medicinal                                                                                                                                                                                 | 16/07/2021 | 19/07/2021    | SmPC, Annex II and PL | To update section 4.4 of the SmPC and section 2 of the PL to implement wording agreed by PRAC in relation to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |        | Guillain-Barré Syndrome.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|----------------------------|
| IB/0024 | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/07/2021 | n/a    |                            |
| II/0015 | Submission of an updated RMP version 3 succession 3 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP and to update the pharmacovigilance plan following the request by PRAC in the outcome of signal assessment procedure on embolic and thrombotic events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify \"anaphylaxis\" as an important identified risk, already reflected in the product information as an adverse reaction. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal product | 08/07/2021 | n/a no | longer authorised          |
| II/0019 | Submission of the interim and primary reports clinical study reports from study D8111C00002, listed as a category 3 study in the RMP. This study is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 01/07/2021 | n/a    |                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | a Phase I/II randomised, double-blind, placebo- controlled, multicentre study in participants aged 18 years or older to determine the safety and immunogenicity of Vaxzevria. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                              |            |               |                     | authorised                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0029 | Sections 4.3, 4.4, 4.8 of the SmPC and sections 2 & 4 of the PL have been updated to add a contraindication in case of capillary leak syndrome and include capillary leask syndrome as a side effect. C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                     | 30/06/2021 | 01/07/2021    | SmPC and PL longer  | Sections 4.3, 4.4, 4.8 of the SmPC and sections 2 & 4 of the PL have been updated to add a contraindication in case of capillary leak syndrome and include capillary leask syndrome as a side effect. |
| IB/0028   | Veterinary Medicinal Products - Other variation Update on Annex II to include a temporary exemption from Article 51, 1(b) of 2001/83/EC until 31 July 2021. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place Medicinal product | 28/06/2021 | 01/07/2021 no | Annex II            | Update on Annex II to include a temporary exemption from Article 51, 1(b) of 2001/83/EC until 31 July 2021.                                                                                           |
| IB/0027   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                               | 28/06/2021 | n/a           |                     |                                                                                                                                                                                                       |
| II/0002   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                             | 24/06/2021 | 01/07/2021    | SmPC, Labelling and | The MAH has provided the primary analysis (based on the 7th December data cut-off) for studies: COV001 (Phase                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | data                                                                                                                                                                                | no   | PL I/II), COV002 (Phase II/III), COV003 (Phase II/III) and COV005 (Phase I/II). These trials were the basis of granting the conditional marketing authorisation. At the time of analysis, participants that received 1 dose of Vaxzevria was extended from 12,021 to 12,282 and from 8,266 to 10,448 those who received 2 doses of Vaxzevria. With 7,158 participants completing >2 months follow-up post-dose 2. Due to the modest extend of both the size and long-term exposure of the safety database, the overall frequencies of adverse events remain barely unchanged to those initially approved. The updated safety data has resulted in the addition of the following adverse drug reactions (with their respective frequencies) in the product information: urticaria (uncommon), abdominal pain (uncommon), pain in extremity (common), influenza-like illness (common), asthenia (common) and lethargy (uncommon). The MAH also took the opportunity to add angioedema with frequency not known, as requested within procedure EMEA/H/C/005675/LEG/036.1. The vaccine efficacy estimates in the product information remained unchanged. The product information wording in relation to shelf-life for opened vials and genetically modified organisms has been longer authorised   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - 22/06/2021 Medicinal product | n/a  | updated for clarity purposes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   | authorised                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025   | Section 6.3 of the SmPC has been updated to introduce conditions for temperature excursions for the unopened vials from refrigerated storage (2°C - 8°C), for a single period of 12 hours up to 30°C or 72 hours down to -3°C. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product 18/06/2021 01/07/2021 product no longer                                                                                             | SmPC Section 6.3 of the SmPC has been updated to introduce conditions for temperature excursions for the unopened vials from refrigerated storage (2°C - 8°C), for a single period of 12 hours up to 30°C or 72 hours down to -3°C. |
| IB/0023/G | This was an application for a group of variations. B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.g.5.c - Implementation of changes foreseen in 28/05/2021 Medicinal                                                | n/a                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------|
| IB/0022/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where product | 27/05/2021 | n/a no     | longer      | authorised                                           |
| II/0016   | batch control/testing takes place B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 27/05/2021 | n/a        |             |                                                      |
| II/0014   | C.I.4 - Change(s) in the SPC, Labelling or PL due to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/05/2021 | 21/05/2021 | SmPC and PL | Thrombocytopenia in combination with thrombo-embolic |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                               |            |            |             | 3 weeks of vaccination. It was also highlighted that any symptoms suggestive of thrombosis and/or thrombocytopenia should trigger immediate medical attention. The package leaflet was updated accordingly. For more information, please refer to the Summary of Product Characteristics. authorised   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018   | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability | 12/05/2021 | n/a        | longer      |                                                                                                                                                                                                                                                                                                        |
| IB/0012   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate  | 28/04/2021 | n/a no     |             |                                                                                                                                                                                                                                                                                                        |
| IB/0013   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product product                                                           | 23/04/2021 | 21/05/2021 | Annex II    | Update of Annex II of the product information to add an alternative site responsible for manufacture of the active substance.                                                                                                                                                                          |
| IAIN/0011 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Medicinal                                                                                                      | 14/04/2021 | 21/05/2021 | SmPC and PL | To update section 4.4 & 4.8 of the SmPC and section 4 of the PL to implement the signal recommendations on hypersensitivity and anaphylaxis (EPITT no 19668) as recommended by PRAC.                                                                                                                   |
| IB/0009/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a                                                          | 14/04/2021 | 21/05/2021 | Annex II    | Update of Annex II of the product information to add an alternative site responsible for manufacture of the active substance.                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product   |            |               |                                  |                                                                                                                                                                                                                                                                                                                     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0010 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                           | 08/04/2021 | 08/04/2021    | SmPC, Annex II and PL            | To update sections 4.4 and 4.8 of the SmPC, Annex II Part D and sections 2 and 4 of the PL to implement further signal recommendations on embolic and thrombotic events. In addition, minor editorial updates are included in section 2 of the PL to improve readability with regards to blood disorder. authorised |
| IAIN/0008 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                               | 06/04/2021 | 08/04/2021 no | SmPC, Annex II and PL longer     | Update of Annex II of the product information to change the name of the site responsible for batch release of the finished product. In addition, minor editorial changes were introduced Annex I, French translation and Annex II, Italian translation.                                                             |
| IB/0005   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product product                                      | 26/03/2021 | 08/04/2021    | Annex II                         | Update of Annex II of the product information to add an alternative site responsible for manufacture of the active substance.                                                                                                                                                                                       |
| IAIN/0007 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                          | 25/03/2021 | 08/04/2021    | SmPC, Annex II, Labelling and PL | To change the invented name of the medicinal product from COVID-19 Vaccine AstraZeneca to VAXZEVRIA                                                                                                                                                                                                                 |
| IB/0006   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation Medicinal                                                           | 24/03/2021 | n/a           |                                  |                                                                                                                                                                                                                                                                                                                     |
| IB/0003/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                        | 23/03/2021 | n/a           |                                  |                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0004 | To update section 4.4 of the SmPC and section 2 of the PL to implement the recommendations on embolic and thrombotic events. C.I.z - Changes (Safety/Efficacy) of Human and 19/03/2021 19/03/2021 SmPC and PL To update section 4.4 of the SmPC and section 2 of the to implement the recommendations on embolic and thrombotic events. longer authorised                |
| IB/0001   | Veterinary Medicinal Products - Other variation B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits 18/02/2021 n/a Medicinal product no                                                                                                                                             |